BIOFRONTERA INC.

BFRI

CIK 0001858685 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$17M
↑+36.2% +$5Mvs FY2024 (Q4)
Operating Income
$7M
↑+109.5% +$4Mvs FY2024 (Q4)
Net Income
$7M
↑+109.5% +$4Mvs FY2024 (Q4)
Gross Profit
$17M
↑+36.2% +$5Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
42/100
  • Profitability
    0ROIC -120.2% (10% = solid, 20%+ = moat)
  • Liquidity
    51Current Ratio 1.52 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 1.65x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +36.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -89.8% · trend -3.4pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$4K
investment in PP&E
Stock-based comp (TTM)
$951K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$29M
everything owned
Total liabilities
$18M
everything owed
Stockholders' equity
$10M
shareholder claim

Recent performance · 22 quarters

Revenue↑+36.2% +$5M
$17M
Net Income↓-17.3% -$980K
$-7M
Free Cash Flow
$-1K
Operating Margin↓-34.8pts
-89.8%

Drill down